

Jonathan M. Barasch, et al.
U.S. Serial No. : Not Yet Known
(§371 National Stage Application of
PCT/US00/12536, filed 4 May 2000)
Filed: Herewith
Page 2

- 14. (Amended) The method of claim 8, wherein the growth factor is TGF α , a FGF-2, or FGF-9 and the effective amount of TGF α , a FGF-2, or FGF-9 is an amount from about 1 ng/ml to about 100 ng/ml.--
- 16. (Amended) The method of claim 8, wherein the growth factor is TIMP-1 or TIMP-2 and the effective amount of TIMP-1 or TIMP-2 is an amount from about 200 ng/ml to about 2 μ g/ml.--
- 18. (Amended) The method of claim 8, wherein the gp130 receptor ligand is a polypeptide comprising a sequence identical to a naturally occurring human gp 130 receptor ligand.--
- 19. (Amended) The method of claim 9, wherein the leukemia inhibitory factor is a polypeptide comprising a sequence identical to a naturally occurring human leukemia inhibitory factor.--
- 20. (Amended) The method of claim 8, wherein the growth factor is a polypeptide comprising a sequence identical to a naturally occurring human growth factor.--

REMARKS

This application is a §371 national stage of PCT International Application No. PCT/US00/12536, filed 4 May 2000, designating the United States of America, which is a continuation-in-part and claiming priority of U.S. Serial No. 09/305,029, filed May 4, 1999. Accordingly, the parent application, PCT International Application No. PCT/US00/12536, is pending today in the United States of America pursuant to 35 U.S.C. §363, and the subject continuation application is co-pending therewith in fulfillment of the provisions of 35 U.S.C. §120.

Claims 1-21 were pending in the subject application. By this Amendment applicants have canceled claims 1-7, 11, 15, 17, and 21 without prejudice or disclaimer. Applicants have hereinabove amended claims 10, 12-14, 16, and 18-20. Applicants maintain that these amendments are made only to make the amended claims dependent on pending claims and do not raise any issue of new matter. Accordingly, upon entry of this Amendment, claims 8-10, 12-14, 16, and 18-20 will be pending and under examination. Pursuant to 37 C.F.R. §1.121(c)(1)(ii), applicants attach hereto as Exhibit A a version of the amended claims marked up to show the changes relative to the previous version thereof.